Open Questions & Loose Threads (Consolidated)

Merged from all five chapters. Each chapter’s list is preserved intact below, grouped by origin, because the questions are phrased against each chapter’s own evidence and section numbers (§ references inside each group refer to sections within the corresponding part). Several themes recur across more than one chapter’s list and are worth reading together:

• the CGRP direction-of-change contradiction and the failure of CGRP drugs in chronic CH (Parts I–II, V, VII);
• the smoking paradox — genetically causal for developing CH, yet quitting doesn’t help, and never-smokers respond worse to oxygen (Parts III, IV, V);
• suicidality prevalence and whether a population-level excess risk exists (Parts III, IV);
• the possible East Asian phenotype — lower chronic share, higher male predominance, restlessness “uncoupling” (Parts I, III, IV);
• chronic→episodic reversion rates (Part IV’s own contested figures; echoed in Part VI);
• the REM-sleep association (Parts II, IV);
• psychedelics as the largest community-vs-trial evidence gap (Parts V, VI, VII);
• and the absence of any Southern-Hemisphere / Australian population data (Parts III, V, VII).

From Parts I–III (history, nature, mechanism, epidemiology)

This section exists because the master brief for this document explicitly requires “unknown” and “contested” to be treated as valid final answers, not gaps to be papered over. The following are genuinely unresolved, contested, or under-researched points raised across the four research passes behind this chapter:

1. Etymology of “suicide headache” is unverified. Two competing origin claims exist (Horton’s 1939 description vs. unnamed French authors) and neither is confirmed by a primary source located in this research pass.
2. Priority for the first historical description of CH is unresolved among historians, with credible claims for Tulp (1641), Willis (1672), de la Pryme (~1702), Suárez de Ribera (1726), and van Swieten (1745) all contested against each other.
3. The “pure hypothalamic generator” model is now considered outdated, but no single replacement model has been definitively established; the “central permissive network” framing (Coppola et al. 2024) is the current best guess, not a settled answer. Hypothalamic volume (VBM) findings are themselves contested — not consistently replicated across studies.
4. CGRP’s direction of change in CH is directly contradicted between the classic literature (elevated) and a recent, well-powered Danish study (lowered) — unresolved, with real treatment-relevant consequences given CGRP-drug trial results.
5. Orexin/hypocretin’s role is unreplicated, with directly contradictory CSF findings between the two key studies (Cevoli 2011 vs. Barloese 2015).
6. Whether smoking is truly causal for CH is a live paradox: strong genetic/Mendelian-randomisation evidence for causality in disease development sits alongside consistent clinical evidence that quitting essentially never improves established disease, and a 2025 meta-analysis found no significant smoking-CH association at all in its own pooled analysis — three lines of evidence that do not yet fit together into one coherent story.
7. Whether the historical male:female sex ratio has genuinely narrowed over time, or whether this is a diagnostic-ascertainment artefact, is contested — the single most population-representative source (Fischera et al. 2008) explicitly could not confirm the narrowing trend that nearly all clinic-cohort studies report.
8. Why Asian clinic-based cohorts show consistently higher male predominance (4.3:1–10:1) than recent Northern European registries (1.47:1–2:1) is not explained in the literature reviewed — genuine biological/cultural difference vs. diagnostic ascertainment difference remains an open question.
9. Why chronic CH is so much less common in East Asian cohorts (2–7.5%) than Western cohorts (10–37%) is likewise unexplained.
10. Whether CH prevalence truly varies by latitude/region is contested between Fischera et al. 2008 (“independent of region”) and a dedicated 2024 latitude review (positive associations found).
11. No population-based CH prevalence study exists anywhere in the Southern Hemisphere, a gap explicitly identified in 2008 and, as of this 2026 research pass, still unaddressed. This includes Australia specifically — no dedicated Australian national or population-based CH prevalence, registry, or demographic study was located in any of the four research passes behind this chapter.
12. Whether CH carries a true population-level excess suicide risk is unresolved: the most recent CH-specific meta-analysis finds no significant excess outside specialised clinical samples, while a large Danish national registry study of headache broadly (including the TAC category containing CH) finds a robust, population-level excess risk. Neither source definitively supersedes the other.
13. Whether female sex independently predicts longer diagnostic delay is contested against a persistent narrative: rigorous primary studies find no significant delay-duration effect by sex, even though the same cohorts often find women are more frequently misdiagnosed at some point along the way — two distinct claims that popular and even some clinical accounts tend to conflate.
14. The indomethacin-response rule distinguishing CH from paroxysmal hemicrania is not perfectly absolute — four documented CH case reports responded to indomethacin, complicating a rule usually taught as a bright line.
15. The restlessness/behaviour “uncoupling” reported in Japanese and Taiwanese cohorts (feeling restless without displaying it) is a single, interesting, minority finding — not yet corroborated or contradicted by comparable studies in other populations.
16. Full verbatim patient quotes from two qualitative studies (Palacios-Ceña et al. 2016; Schindler et al. 2021’s “shoe polish” survey) could not be recovered from accessible abstract-only pages during this research pass, and would need full-text institutional access to extract directly.
17. No dedicated Swedish- or Chinese-language historical source, and no dedicated Italian-language pathophysiology-specific primary research beyond a single 1998 melatonin study, were located — these may simply reflect gaps in this research pass rather than true absences in the literature.
18. Some sources could not be fetched at all due to publisher paywalls or site-level access blocks during this research (notably several SAGE/Cephalalgia full texts, one PMC patient-story compilation, and a Springer review on cluster-headache behaviour) — figures drawn from these are based on abstracts or secondary citations and should be re-verified against full text before being treated as final in any downstream use of this chapter.

From Part IV (types, diagnosis and differentials)

• Chronic-to-episodic reversion rate is genuinely contested, not just imprecisely measured. The Danish Headache Center’s most recent interview-based cohort puts 5-year chronic→episodic reversion at 25%; Manzoni’s long-term natural history data put it at 32.6%; the 2023 European Academy of Neurology guideline describes reversion as occurring “rarely.” These are not compatible framings of the same fact, and no source in this pass reconciled them. Possible explanations (different cohort eras, treatment intensity, or definitions of “reversion”) are not confirmed.
• Episodic-to-chronic conversion rate estimates cluster around 12–20% in recent structured cohorts but range from 4% to 15% depending on follow-up length and country — treat any single-number claim (“X% convert to chronic”) with suspicion; the true figure is clearly time-dependent and rises with longer follow-up.
• REM sleep association: contested. Early studies strongly link nocturnal CH attacks to REM sleep, especially in episodic CH; more recent work finds no significant REM association at all, and chronic CH appears to lack the REM link altogether. Unresolved.
• OSA and CH — causal or parallel? The literature explicitly states this remains undetermined: OSA could trigger CH attacks via hypoxic/desaturation mechanisms, or both conditions could be independent downstream effects of hypothalamic dysfunction. No prospective interventional trial (e.g. CPAP vs no CPAP) resolving this was found.
• Alcohol and population-level CH risk: two peer-reviewed cohort studies produce directly opposing risk ratios for non-drinkers vs drinkers; a meta-analysis could not adjudicate. The in-bout vs out-of-bout attack-triggering effect is well established; the broader epidemiological relationship between alcohol use and CH susceptibility is not.
• Weather/temperature as a CH trigger is now a genuine, sourced conflict rather than an unverified claim. A large Taiwanese nationwide study found temperature specifically associated with new bout onset; a 2026 Spanish primary-care time-series study found no significant association between any of 14 climatic variables (including temperature and barometric pressure) and CH consultation frequency. Barometric pressure specifically has no CH-specific peer-reviewed confirmation as a trigger found in this pass — the common patient belief in “pressure drops trigger attacks” currently rests on migraine-literature extrapolation and community report rather than CH-specific primary data.
• Altitude as a CH trigger: now supported by at least one specific peer-reviewed case report (oxygen-responsive, sumatriptan-refractory attack at altitude), but this is n=1 evidence. No population-level or cohort data quantifying altitude-triggering frequency across the general CH population was found — treat “altitude triggers CH” as plausible and case-documented, not established at a population level.
• Suicidality prevalence range: estimates vary enormously by study design, from ~8% lifetime ideation (population-representative meta-analysis) to 55% (self-selected US patient survey) and 47% (case-control community-recruited sample). Whether this reflects sampling bias, definitional differences (ideation vs risk vs attempts), or genuine subpopulation differences is unresolved.
• Smoking and CH severity/cessation: strong association between smoking and more severe CH phenotype is established, but a causal or even correlational benefit from quitting is not — most patients report no change after cessation, and this itself is a striking, still poorly explained finding given smoking’s causal role in most other diseases it is linked to.
• SUNCT vs SUNA as one disorder or two: increasingly treated as a spectrum/single entity by researchers, but ICHD-3 retains them as formally separate diagnoses pending further study — an active taxonomic tension.
• Possible East Asian phenotype difference: Japanese clinic cohorts report markedly lower chronic-CH prevalence (as low as 2.8% vs 10–20% in Western cohorts) and a distinctive “uncoupling” between subjective restlessness and observed restless behaviour during attacks. The source authors themselves frame this as a genuine ethnic/phenotypic difference rather than an artefact, but this remains a minority, under-replicated finding and has not been independently confirmed in large multi-ethnic comparative cohorts.
• German national patient-registry data (CSG surveys): Germany’s national CH patient association has run recent surveys on sex differences and psychological burden in CH, but this research did not retrieve full published results from these specific surveys — flagged for direct follow-up with clusterkopf.de rather than treated as sourced here.
• Community self-diagnosis narrative: widely repeated across patient forums that many people self-diagnose from internet research before a clinician confirms it. This is no longer purely anecdotal — the Dutch cohort study found a specific figure of 16% self-diagnosing from books/magazines — but broader, more recent quantification (e.g. specifically “internet search” as the self-diagnosis route, as commonly described in forums today) was not found and remains anecdotal at the more specific level.
• Diagnostic delay figures are inconsistent even within the same country (e.g. Spain: 4.9 years in one national report vs 7.8 years in a separate regional registry; Germany: 44 months in one source vs 9.6 years in another cohort). This likely reflects genuine differences between clinic-referred and population-representative samples, but no single study in this pass reconciled the within-country discrepancies directly.

From Part V (treatment)

Genuinely contested or unresolved in the literature itself

• Oxygen flow rate: no consensus, and the one head-to-head trial points the wrong way. Guidance ranges from Japan’s 7 L/min to Clusterbusters’ ≥15 to community protocols of 25–40 L/min, yet the only head-to-head trial (Dirkx 2018) found no advantage for 12 L/min over 7 L/min and hinted at the reverse, while EAN cites an odds ratio in the opposite direction with a confidence interval that crosses 1 (0.58–24.28). Unresolved. The 25–40 L/min figures used in parts of the community have never been formally trialled at all — plausible extrapolation from demand-valve physiology, not demonstrated fact (Section 1.1).
• Hyperventilate on oxygen, or don’t? German (DMKG) guidance says no; some community sources say yes, as fast as possible. Contested, with a plausible but unverified reconciliation that it depends on whether the gas is genuinely undiluted (Section 1.1).
• Oxygen concentrators: useless or adequate? Depends entirely on target flow rate and is stated inconsistently across sources depending on which flow rate they assume (Section 1.1).
• Melatonin in chronic CH: one small positive trial in which both chronic participants failed, one small negative trial, and case reports of chronic patients becoming headache-free. Genuinely unresolved, not merely under-studied (Section 3.4).
• Verapamil formulation (immediate-release vs sustained-release): the dominant English-language community view and at least one German clinic protocol disagree on this directly. Not resolved by the evidence assembled here (Section 3.1).
• CGRP mAbs in episodic CH: the two 2026 meta-analyses agree there is no benefit in chronic CH, but reach different conclusions on episodic CH (OR 1.65, p=0.02 vs no significant effect) purely because of different endpoint choices and inclusion criteria. This is a methodological disagreement, not a data disagreement, and is presented as such rather than resolved in either direction (Section 3.6).
• The smoking paradox: never having smoked predicts a worse oxygen response in both a clinical study and a 493-person community survey, while smoking is simultaneously used as a supply-eligibility barrier for home oxygen in the UK. No mechanistic explanation exists. Unknown.

Documented but not formally studied — flagged as community signal, not established finding

• Serotonergic psychedelics (LSD, psilocybin, ergoline alkaloids) rank highest of all self-reported prophylactics in citizen-science surveys (~75% efficacy), above verapamil and corticosteroids, despite almost no randomised evidence existing at the time of that survey data. This is the single largest gap identified anywhere in this chapter between community-reported efficacy and formal trial evidence (Section 7.2). It falls outside the acute/bridge/preventive/neuromodulation/access scope this chapter was scoped to, but is flagged here so it is not lost, and belongs explicitly in any future chapter on non-conventional or emerging treatments.
• Hair loss on galcanezumab, reported independently across at least three separate r/clusterheads threads, does not appear in any labelled adverse-event list for the drug (Section 3.6 / 7.6).
• Tachyphylaxis (loss of effect) 6–24 months into CGRP mAb treatment, reported repeatedly by community members, has never been formally studied (Section 3.6 / 7.6).
• Warfarin’s NNT of 2.6 (95% CI 1.7–5.5) — the single best number-needed-to-treat figure anywhere in this chapter — comes from one 2011 trial that has never been replicated in fifteen years. Flagged as an odd, isolated finding, not a treatment recommendation (Section 3.5 / 7.7).

Access and regulatory gaps specific to Australia that remain unverified or unresolved despite this research pass

• gammaCore/nVNS reimbursement pathways in the EU/Germany: UNKNOWN — not verified in this research pass (Section 5.4).
• Current verified Australian dollar figures for medical oxygen cylinder hire, sumatriptan autoinjector PBS co-payment, and GON block MBS rebate were not locatable from primary sources within this research session. Anyone relying on these should check directly with a supplier (BOC, Air Liquide, Coregas) and the current PBS/MBS schedules rather than treating any figure elsewhere in this chapter as current (Section 1 / 5.1).
• US formulary tier placement for several off-label preventives was not verified for specific insurers (Section 5.2).

Sourcing limitations disclosed by the research process itself

• Two PubMed records could not be retrieved directly during this research pass and were sourced second-hand instead: Pearson et al. 2019 (PMID 30632614, the large Clusterbusters/CHQ survey, quoted via Guo et al. 2019) and a GON block meta-analysis (PMID 32781922, not incorporated at all — there may be pooled GON-block data this chapter does not reflect). A valproate RCT (PMID 12047460) was also blocked on direct fetch and is sourced via PMC8748342’s reproduction of the trial data instead (Sections 1, 2, 3).
• No systematic search of Chinese-language literature was performed for any section of this chapter. Italian (SISC), Japanese (JHS), German (DMKG/AWMF) and Swiss guideline PDFs were located but not all individually extracted within the research session’s budget — the non-English findings actually used in the body text came specifically from Schmerzklinik Kiel (German), a 2025 Czech review, a SciELO-hosted lithium review, and the Japanese Headache Society CQ1 guideline. This is stated explicitly so no reader assumes the full text of every located non-English guideline was read and incorporated.
• This chapter’s own thoroughness is uneven by design of the parallel research process that produced it: the acute/bridge draft and the preventive draft were each produced independently and did not cross-reference each other’s treatment categories, so some cross-cutting connections (e.g. between bridge corticosteroids and the broader steroid literature, or between GON blocks as bridge therapy and GON blocks as a chronic-CH refractoriness criterion in Section 4.0) may be less tightly integrated than a single continuous research pass would have produced. Section 7 above is this document’s attempt to repair that after the fact, but it should not be assumed exhaustive.
• Reddit thread dates and participant counts throughout this chapter are approximate, derived from page content rather than platform metadata, where exact dates were not stated on the fetched page.

From Part VI (citizen science and community knowledge)

This section was revised in a follow-up research pass (August 2026) that specifically targeted the items below. Resolved or substantially updated items are marked accordingly; several turned out to resolve toward disappointing or null answers rather than positive ones — which is itself useful information.

• RESOLVED (negatively): the Vitamin D3 RCT outcome is now known — the trial failed. NCT04570475 was terminated in 2024 after randomising only 27 of its intended participants, citing “low number met criteria to randomize,” and never posted results preprint / trial[^23]. The Batch protocol’s flagship formal test no longer exists as a pending question; it exists as a failed attempt. Whether a differently designed trial (e.g. one not requiring D3-naïve participants) could still succeed is a new open question this raises.
• Still unresolved: no full peer-reviewed paper for the D3 survey. The 110-patient D3 survey still exists only as the 2014 Neurology conference abstract; nothing new was found on this point.
• Still unresolved: mechanism of psilocybin/LSD/BOL-148 efficacy in CH. No mechanistic resolution was found. If anything, the newly identified Schindler/Wold 2026 DMT survey abstract [^81] suggests the community-and-clinic collaboration is now testing a third psychedelic class, which will add data without yet answering the underlying “why does intensity not predict benefit” question.
• Still unresolved: BOL-148’s non-hallucinogenic status is itself contested (unchanged from original chapter; not specifically re-investigated in this update).
• Still unresolved: exercise as trigger or treatment. No mechanistic account distinguishing responder subgroups was found in this update.
• Still unresolved: no aggregated CH-specific wearable/app dataset. Not specifically re-investigated in this update; treat as unchanged.
• RESOLVED (negatively, and now more strongly confirmed): kudzu has never been formally trialled, seventeen years after the original 2009 case series explicitly called for an RCT. A fresh check found no registered kudzu headache trial anywhere peer-reviewed[^89].
• UPDATED: the Australian PEACE psilocybin trial has not started recruiting as of August 2026. The trial’s own lead investigator stated in September 2025 that recruitment was expected to begin in the second half of 2026; a March 2026 webinar still described it as “upcoming.” No ANZCTR/ClinicalTrials.gov registration number could be located in this research, which is itself worth someone manually checking at anzctr.org.au preprint / trial[^85][^86]. Results are now a 2027-or-later prospect, not a “pending” near-term one.
• RESOLVED (negatively, and now more strongly confirmed): energy drink/caffeine aborts have never been formally tested, and a fresh literature check found nothing that changes this peer-reviewed[^88].
• PARTIALLY RESOLVED: cross-cultural and non-English community data. Targeted native-language research now shows a clear pattern rather than a blank: Germany has genuine patient-driven citizen science with a peer-reviewed output (Clusterkopfschmerz-Radar/CLUE, feeding into a 2021 BMC Neurology paper) citizen sciencepeer-reviewed[^67][^69], while Scandinavian, Italian, and Spanish communities have well-organised patient associations but no published patient-collected datasets of their own, and no Japanese or Chinese patient-run, data-collecting CH community could be located in indexable sources — though the Chinese negative result is weaker, since much peer support plausibly happens in non-indexable WeChat/Baidu Tieba channels this research could not assess [COMMUNITY-REPORT / unverified][^70][^72][^74][^75][^76][^77][^78][^79][^80]. The open question narrows from “is there data out there we haven’t found?” to “why has only the German community converted patient-logged data into a publication, and could the German CLUE/mitforschen.org model be replicated elsewhere?”
• NEW: EPOCH (NCT04280055) is not the completed 30%-reduction success this chapter originally implied. It was terminated early due to COVID-19 recruitment problems, reaching only 10 participants; the earlier framing should be treated as corrected here preprint / trial[^36].
• NEW: a DMT-in-cluster-headache survey (Schindler, Lenaburg, Wold, 2026) is underway as an interim conference abstract, extending the psychedelics research agenda to a third compound class with direct community-founder co-authorship; full results are not yet available and should be watched for citizen sciencepeer-reviewed[^81].
• NEW: BOL-148/Ceruvia’s German Phase 1/2 trial has still not dosed a single participant as of this update (August 2026), despite a fresh $8M raise; do not treat the Q4 2026 enrolment / Q2 2027 data timeline as assured given this programme’s decade-plus history of slipping schedules preprint / trial[^40].

From Part VII (the frontier)

• The hypothalamic-imaging contradiction is unresolved. A 69-patient Chinese 7T study found increased hypothalamic volume; a tightly-controlled 26-patient Italian study found none at all on the same question. Both are recent, both are peer-reviewed, and they directly disagree. [Contested]
• The direction of IL-1β in CH is inconsistent across the literature, and the earlier draft of this chapter got it backwards. Even within the single largest cytokine study, the inflammasome hypothesis’s own authors acknowledge the conflict openly. Whether chronic CH is genuinely pro-inflammatory (as the Danish plasma data suggest) remains unreplicated by an independent group. [Contested]
• CSF and serum cytokines move in opposite directions in the same CH patients (Swedish study). This means most published “CH is inflammatory” claims based on blood alone may not reflect what is happening in the central nervous system. [Unresolved methodological problem]
• Whether the inflammasome hypothesis reflects real pathophysiology or is an artefact of gene-annotation inference is genuinely open — no study has yet measured actual inflammasome (NLRP3/caspase-1) activity in CH patients.
• Whether core circadian clock genes matter genetically is disputed within the last 12 months of literature itself: a large critical review says no, a newer (April 2026) targeted-genotyping study says yes. Both are recent and neither has been independently replicated yet. [Contested]
• PACAP has the strongest pharmacological rationale of any drug target in CH and precisely zero CH-specific trials. Whether any sponsor will ever run one — rather than leaving CH patients to benefit only incidentally from migraine drug development — is unknown and worth actively monitoring.
• Orexin has never actually been tested in cluster headache, despite a real anatomical rationale, because the only headache trial ever run (in migraine, 2015) was negative and nobody has revisited the mechanism in the population where it might plausibly matter most. This is a genuine, unexploited research gap, not a settled negative.
• Japan’s UMIN-CTR registry could not be retrieved during this research pass despite three attempts (direct fetch, content-fetch service, and browser rendering all failed). A Japanese CH trial invisible to jRCT cannot currently be ruled out, though the risk is judged low.
• Three Chinese trial registrations (ChiCTR) could not be resolved to phase, dates, or endpoints because ChiCTR’s detail pages are keyed by an internal ID not exposed in search results.
• The MRFF PEACE psilocybin trial’s funding amount is genuinely undisclosed in both public announcements found.
• Whether Clusterbusters’ 85% asset drawdown between 2022 and 2023 reflects a real capacity constraint on the organisation’s future citizen-science and advocacy work is unknown; FY2024/2025 financial filings were not yet available to check.
• The claim that CH is globally more prevalent than MS rests on a CH prevalence estimate with a wide confidence interval (one-year prevalence 53/100,000, 95% CI 26–95) — the comparison is directionally likely true but not as tightly bounded as a single point estimate implies.
• There is still no official government audit of cluster-headache-specific research funding anywhere in the world. The NIH figures in this chapter are this pass’s own reconstruction from grant-level RePORTER data, not an official NIH statistic — precisely the gap that the field’s own advocacy literature (Orr & Shapiro 2022, “The elephant in the room”) has been pointing at for years without it being filled.
• No James Lind Alliance–style formal priority-setting partnership has ever been run for cluster headache, unlike several adjacent neurological conditions — the 2026 Australian patient survey is currently the closest thing the field has to one, and it was unfunded.